LY86

Across TCGA pan-cancer cohorts, LY86 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LY86’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LY86 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LY86 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

KIRC, THCA, and COAD are the cancer types where LY86 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LY86 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+2.815	<.001	12	view →
THCA	Male	II,III,IV	+1.752	<.001	10	view →
COAD	Female	All	−0.856	<.001	10	view →
KIRP	Male	All	+2.228	<.001	9	view →
LUAD	Male	II,III,IV	−1.508	<.001	9	view →
LUSC	Male	II,III,IV	−2.528	<.001	8	view →
STAD	All	II,III,IV	+1.198	.001	6	view →
BRCA	Female	All	+0.595	<.001	6	view →
PAAD	All	All	−2.429	.021	2	view →
CHOL	All	II,III,IV	−1.224	.047	2	view →
UCEC	All	All	−0.891	<.001	2	view →
HNSC	Female	II,III,IV	+0.613	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LY86–KIRC

Open the KIRC breakdown →